BioLife Solutions, Inc. (NASDAQ:BLFS) Position Increased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 40.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 821,764 shares of the medical equipment provider's stock after purchasing an additional 236,267 shares during the period. Rockefeller Capital Management L.P. owned 1.77% of BioLife Solutions worth $21,333,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. FMR LLC grew its holdings in shares of BioLife Solutions by 470.6% during the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider's stock worth $333,000 after buying an additional 10,983 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after purchasing an additional 670 shares during the period. State Street Corp lifted its stake in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after purchasing an additional 95,788 shares during the period. Barclays PLC boosted its holdings in shares of BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock worth $1,613,000 after purchasing an additional 10,803 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after purchasing an additional 18,473 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. StockNews.com raised shares of BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday, April 8th. Finally, HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.17.

BioLife Solutions Trading Down 1.6 %

BLFS stock traded down $0.35 during midday trading on Friday, reaching $21.91. 529,574 shares of the company's stock traded hands, compared to its average volume of 375,330. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a fifty-two week low of $15.72 and a fifty-two week high of $29.55. The business has a 50-day moving average price of $24.62 and a two-hundred day moving average price of $25.27. The company has a market capitalization of $1.04 billion, a P/E ratio of -20.67 and a beta of 1.93.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the business posted ($0.21) EPS. Equities research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, insider Sarah Aebersold sold 2,695 shares of BioLife Solutions stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the sale, the insider now directly owns 43,165 shares in the company, valued at $1,098,117.60. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Troy Wichterman sold 4,151 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the transaction, the chief financial officer now owns 116,809 shares of the company's stock, valued at approximately $2,920,225. This trade represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,127 shares of company stock worth $1,676,533 in the last quarter. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.